Cemiplimab for Secondary Angiosarcomas
Condition(s):Secondary Angiosarcoma; Locally Advanced Sarcoma; MetastasisLast Updated:February 3, 2022Recruiting
Include Studies Not Open or Pending
Condition(s):Secondary Angiosarcoma; Locally Advanced Sarcoma; MetastasisLast Updated:February 3, 2022Recruiting
Condition(s):Merkel Cell Carcinoma; Cutaneous Squamous Cell CarcinomaLast Updated:February 22, 2024Recruiting
Condition(s):Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Basal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer; Oropharynx Squamous Cell CarcinomaLast Updated:February 20, 2024Recruiting
Condition(s):Colon CancerLast Updated:March 28, 2024Not yet recruiting
Condition(s):Non-small Cell Lung Cancer (NSCLC)Last Updated:February 22, 2024Recruiting
Condition(s):Metastatic Uveal MelanomaLast Updated:November 7, 2023Recruiting
Condition(s):Cutaneous Squamous Cell Carcinoma; Basal Cell CarcinomaLast Updated:February 26, 2024Recruiting
Condition(s):Advanced Non-Small Cell Lung CancerLast Updated:February 13, 2024Recruiting
Condition(s):Non-Small Cell Lung CancerLast Updated:March 15, 2024Recruiting
Condition(s):Recurrent Skin Squamous Cell Carcinoma; Resectable Skin Squamous Cell Carcinoma; Stage I Skin Cancer; Stage II Skin Cancer; Stage III Skin CancerLast Updated:May 26, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.